⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Supplementary Figure S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma

Paolo Strati Lei Feng Andrey Tyshevich Darya Shavronskaya Julia Alesse Noel English Elizabeth Sheehan Nikita Syzrantsev Alexander Nesmelov Tony Zhuang Dai Chihara Jason R. Westin Sairah Ahmed Luis Fayad Jared Henderson Karin M. Dent Elizabeth McChesney Sattva S. Neelapu Christopher R. Flowers

View Full Paper

Ask AI

Bookmark

Share

Key Points

The trial examines immune cell changes during treatment, highlighting the role of combination therapy.
Initial findings show alterations in T cells and myeloid cells, suggesting immune modulation effects.
This phase I trial involved patients with B-cell non-Hodgkin lymphoma receiving targeted therapies.
Observations call for further studies to explore the potential of optimizing immune response in lymphoma.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I trial tests evorpacept's impact on T cells and myeloid cells in lymphoma patients, indicating potential immune response changes.

Abstract

Changes in T cells and myeloid cells during treatment

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strati et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a43 https://doi.org/10.1158/1078-0432.30255119

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
2Supplementary Figure S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
3Supplementary Figure S4 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
4Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
5Data from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025